202 related articles for article (PubMed ID: 16159024)
1. Recent developments in cathepsin K inhibitor design.
Grabowskal U; Chambers TJ; Shiroo M
Curr Opin Drug Discov Devel; 2005 Sep; 8(5):619-30. PubMed ID: 16159024
[TBL] [Abstract][Full Text] [Related]
2. 6. Cathepsin K inhibitors: their potential as anti-osteoporosis agents.
Deaton DN; Kumar S
Prog Med Chem; 2004; 42():245-375. PubMed ID: 15003723
[No Abstract] [Full Text] [Related]
3. An orally active cathepsin K inhibitor, furan-2-carboxylic acid, 1-{1-[4-fluoro-2-(2-oxo-pyrrolidin-1-yl)-phenyl]-3-oxo-piperidin-4-ylcarbamoyl}-cyclohexyl)-amide (OST-4077), inhibits osteoclast activity in vitro and bone loss in ovariectomized rats.
Kim MK; Kim HD; Park JH; Lim JI; Yang JS; Kwak WY; Sung SY; Kim HJ; Kim SH; Lee CH; Shim JY; Bae MH; Shin YA; Huh Y; Han TD; Chong W; Choi H; Ahn BN; Yang SO; Son MH
J Pharmacol Exp Ther; 2006 Aug; 318(2):555-62. PubMed ID: 16699068
[TBL] [Abstract][Full Text] [Related]
4. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.
Xiang A; Kanematsu M; Kumar S; Yamashita D; Kaise T; Kikkawa H; Asano S; Kinoshita M
Bone; 2007 May; 40(5):1231-7. PubMed ID: 17347064
[TBL] [Abstract][Full Text] [Related]
5. Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate.
Stroup GB; Lark MW; Veber DF; Bhattacharyya A; Blake S; Dare LC; Erhard KF; Hoffman SJ; James IE; Marquis RW; Ru Y; Vasko-Moser JA; Smith BR; Tomaszek T; Gowen M
J Bone Miner Res; 2001 Oct; 16(10):1739-46. PubMed ID: 11585335
[TBL] [Abstract][Full Text] [Related]
6. A highly potent inhibitor of cathepsin K (relacatib) reduces biomarkers of bone resorption both in vitro and in an acute model of elevated bone turnover in vivo in monkeys.
Kumar S; Dare L; Vasko-Moser JA; James IE; Blake SM; Rickard DJ; Hwang SM; Tomaszek T; Yamashita DS; Marquis RW; Oh H; Jeong JU; Veber DF; Gowen M; Lark MW; Stroup G
Bone; 2007 Jan; 40(1):122-31. PubMed ID: 16962401
[TBL] [Abstract][Full Text] [Related]
7. Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo.
Votta BJ; Levy MA; Badger A; Bradbeer J; Dodds RA; James IE; Thompson S; Bossard MJ; Carr T; Connor JR; Tomaszek TA; Szewczuk L; Drake FH; Veber DF; Gowen M
J Bone Miner Res; 1997 Sep; 12(9):1396-406. PubMed ID: 9286755
[TBL] [Abstract][Full Text] [Related]
8. Natural inhibitors targeting osteoclast-mediated bone resorption.
Zeng GZ; Tan NH; Hao XJ; Mu QZ; Li RT
Bioorg Med Chem Lett; 2006 Dec; 16(24):6178-80. PubMed ID: 17027271
[TBL] [Abstract][Full Text] [Related]
9. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.
Tavares FX; Deaton DN; Miller AB; Miller LR; Wright LL; Zhou HQ
J Med Chem; 2004 Oct; 47(21):5049-56. PubMed ID: 15456248
[TBL] [Abstract][Full Text] [Related]
11. Cathepsin K: a therapeutic target for bone diseases.
Zhao Q; Jia Y; Xiao Y
Biochem Biophys Res Commun; 2009 Mar; 380(4):721-3. PubMed ID: 19338743
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin K inhibitors: a novel target for osteoporosis therapy.
Stoch SA; Wagner JA
Clin Pharmacol Ther; 2008 Jan; 83(1):172-6. PubMed ID: 18073778
[TBL] [Abstract][Full Text] [Related]
13. [Odanacatib (MK-0822)].
Nagase Y; Tanaka S
Clin Calcium; 2011 Jan; 21(1):59-62. PubMed ID: 21187595
[TBL] [Abstract][Full Text] [Related]
14. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models.
Ravikumar M; Pavan S; Bairy S; Pramod AB; Sumakanth M; Kishore M; Sumithra T
Chem Biol Drug Des; 2008 Jul; 72(1):79-90. PubMed ID: 18498326
[TBL] [Abstract][Full Text] [Related]
15. Structure-based development of pyridoxal propionate derivatives as specific inhibitors of cathepsin K in vitro and in vivo.
Katunuma N; Matsui A; Inubushi T; Murata E; Kakegawa H; Ohba Y; Turk D; Turk V; Tada Y; Asao T
Biochem Biophys Res Commun; 2000 Jan; 267(3):850-4. PubMed ID: 10673380
[TBL] [Abstract][Full Text] [Related]
16. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
17. Cathepsin K, osteoclastic resorption, and osteoporosis therapy.
Zaidi M; Troen B; Moonga BS; Abe E
J Bone Miner Res; 2001 Oct; 16(10):1747-9. PubMed ID: 11585336
[No Abstract] [Full Text] [Related]
18. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis.
Robichaud J; Black WC; Thérien M; Paquet J; Oballa RM; Bayly CI; McKay DJ; Wang Q; Isabel E; Léger S; Mellon C; Kimmel DB; Wesolowski G; Percival MD; Massé F; Desmarais S; Falgueyret JP; Crane SN
J Med Chem; 2008 Oct; 51(20):6410-20. PubMed ID: 18811135
[TBL] [Abstract][Full Text] [Related]
19. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis].
Nakamura T
Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826
[TBL] [Abstract][Full Text] [Related]
20. 5-Aminopyrimidin-2-ylnitriles as cathepsin K inhibitors.
Morley AD; Kenny PW; Burton B; Heald RA; Macfaul PA; Mullett J; Page K; Porres SS; Ribeiro LR; Smith P; Ward S; Wilkinson TJ
Bioorg Med Chem Lett; 2009 Mar; 19(6):1658-61. PubMed ID: 19231183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
